We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Antihypertensive Agents Reduce Heart Biomarkers Levels

By LabMedica International staff writers
Posted on 02 Jan 2018
Print article
Image: The Troponin T hs assay kit improves the detection and exclusion of myocardial injury in the early stages (Photo courtesy of Roche Diagnostics).
Image: The Troponin T hs assay kit improves the detection and exclusion of myocardial injury in the early stages (Photo courtesy of Roche Diagnostics).
High blood pressure (BP) is associated with an increased rate of cardiovascular events and mortality. Cardiovascular biomarkers are able to predict long-term risk in the general population, particularly in diseased cohorts.

Two different antihypertensive regimens had the effect of lowering blood pressure levels in patients while reducing both cardiac troponin levels measured by a high-sensitivity assay (hs-cTn) and B-type natriuretic peptide (BNP) concentrations.

Scientists at University Heart Center Hamburg (Hamburg, Germany) randomized into two cohorts of hypertensive patients at one healthcare center. In one group, 251 individuals received 80 mg telmisartan and 5 mg amlodipine, while in the other, 230 received 40 mg olmesartan and 12.5 mg hydrochlorothiazide. Patients prior to randomization and after six months had measurements of their blood pressure, hs-cTn I and T, BNP, and N-terminal-pro-BNP (NT-proBNP).

Various assays from Roche (Basel, Switzerland) and Abbott Laboratories (Abbott Park, IL, USA) were used to measure the cardiovascular biomarkers. The team reported that hs-cTnI concentrations declined markedly in both study groups and in the overall population dropped from 4.6 ng/L to 4.2 ng/L. In a subgroup analysis, the investigators discovered that male patients experienced a much higher reduction in hs-cTnI concentrations than their female counterparts. By comparison, hs-cTnT’s measurability was just 26.2% in the overall study population. Concentrations for this biomarker did not change after the intervention. BNP and NT-proBNP concentrations also were reduced after six months: from 15.0 ng/L to 12.4 ng/L and from 64.8 ng/L to 53.3 ng/L, respectively.

The authors concluded that they had determined that reducing blood pressure in patients led to a reduction in hs-cTnI, BNP, and NT-proBNP concentrations after half a year’s treatment with antihypertensive therapies. This effect was stronger when the combination of an angiotensin-receptor blocker with a calcium-channel blocker was used as compared to an angiotensin-receptor blocker and a diuretic. The study was published in the December 2017 issue of the journal Clinical Chemistry.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.